Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 5Active not recruiting 4Not yet recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 11Plasma cell 4Other hematologic neoplasm 3Dermatologic 3Other solid neoplasm 2CNS 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Multiple Myeloma 4

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × tocilizumab × Plasma cell × Clear all
NCT05646836 2026-05-14

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Genentech, Inc.

Phase 1 Active not recruiting
90 enrolled
Plasma cell

Multiple Myeloma

NCT05535244 2026-05-07

CAMMA 2

Hoffmann-La Roche

Phase 1/2 Active not recruiting
90 enrolled
Plasma cell

Multiple Myeloma

NCT04910568 2026-03-19

CAMMA 1

Genentech, Inc.

Phase 1 Active not recruiting
126 enrolled
Plasma cell

Multiple Myeloma

NCT05391750 2026-02-17

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Emory University

Phase 1 Active not recruiting
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡